Literature DB >> 32384154

The ectodomain of matriptase-2 plays an important nonproteolytic role in suppressing hepcidin expression in mice.

Caroline A Enns1, Shall Jue1, An-Sheng Zhang1.   

Abstract

Matriptase-2 (MT2), encoded by TMPRSS6, is a membrane-anchored serine protease that plays a key role in suppressing hepatic hepcidin expression. MT2 is synthesized as a zymogen and undergoes autocleavage for activation. Previous studies suggest that MT2 suppresses hepcidin by cleaving hemojuvelin and other components of the bone morphogenetic protein-signaling pathway. However, the underlying mechanism is still debatable. Here we dissected the contributions of the nonproteolytic and proteolytic activities of Mt2 by taking advantage of Mt2 mutants and Tmprss6-/- mice. Studies of the protease-dead full-length Mt2 (Mt2S762A) and the truncated Mt2 that lacks the catalytic domain (Mt2mask) indicate that the catalytic domain, but not its proteolytic activity, was required for Mt2 to suppress hepcidin expression. This process was likely accomplished by the binding of Mt2 ectodomain to Hjv and Hfe. We found that Mt2 specifically cleaved the key components of the hepcidin-induction pathway, including Hjv, Alk3, ActRIIA, and Hfe, when overexpressed in hepatoma cells. Nevertheless, studies of a murine iron-refractory iron-deficiency anemia-causing mutant (Mt2I286F) in the complement protein subcomponents C1r/C1s, urchin embryonic growth factor, and bone morphogenetic protein 1 domain indicate that Mt2I286F can be activated, but it exhibited a largely compromised ability to suppress hepcidin expression. Coimmunoprecipitation analysis revealed that Mt2I286F, but not Mt2S762A, had reduced interactions with Hjv, ActRIIA, and Hfe. In addition, increased expression of a serine protease inhibitor, the hepatocyte growth factor activator inhibitor-2, in the liver failed to alter hepcidin. Together, these observations support the idea that the substrate interaction with Mt2 plays a determinant role and suggest that the proteolytic activity is not an appropriate target to modulate the function of MT2 for clinical applications.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32384154      PMCID: PMC7441170          DOI: 10.1182/blood.2020005222

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  59 in total

1.  The role of hepatocyte hemojuvelin in the regulation of bone morphogenic protein-6 and hepcidin expression in vivo.

Authors:  An-Sheng Zhang; Junwei Gao; Dwight D Koeberl; Caroline A Enns
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

2.  Sustained correction of bleeding disorder in hemophilia B mice by gene therapy.

Authors:  L Wang; K Takabe; S M Bidlingmaier; C R Ill; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

3.  Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis.

Authors:  Karin List; Christian C Haudenschild; Roman Szabo; WanJun Chen; Sharon M Wahl; William Swaim; Lars H Engelholm; Niels Behrendt; Thomas H Bugge
Journal:  Oncogene       Date:  2002-05-23       Impact factor: 9.867

4.  Distinct Developmental Functions of Prostasin (CAP1/PRSS8) Zymogen and Activated Prostasin.

Authors:  Stine Friis; Daniel H Madsen; Thomas H Bugge
Journal:  J Biol Chem       Date:  2015-12-30       Impact factor: 5.157

5.  Hepatocyte growth factor activator inhibitor type 2 (HAI-2) modulates hepcidin expression by inhibiting the cell surface protease matriptase-2.

Authors:  Eva Maurer; Michael Gütschow; Marit Stirnberg
Journal:  Biochem J       Date:  2013-03-15       Impact factor: 3.857

6.  Discovery and Development of TMPRSS6 Inhibitors Modulating Hepcidin Levels in Human Hepatocytes.

Authors:  François Béliveau; Aarti Tarkar; Sébastien P Dion; Antoine Désilets; Mariana Gabriela Ghinet; Pierre-Luc Boudreault; Catherine St-Georges; Éric Marsault; Daniel Paone; Jon Collins; Colin H Macphee; Nino Campobasso; Arthur Groy; Josh Cottom; Michael Ouellette; Andrew J Pope; Richard Leduc
Journal:  Cell Chem Biol       Date:  2019-09-19       Impact factor: 8.116

7.  Mouse matriptase-2: identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult and embryonic tissues.

Authors:  John D Hooper; Luisa Campagnolo; Goodarz Goodarzi; Tony N Truong; Heidi Stuhlmann; James P Quigley
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

Review 8.  Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis.

Authors:  Andrew J Ramsay; John D Hooper; Alicia R Folgueras; Gloria Velasco; Carlos López-Otín
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

9.  Identification of TMPRSS6 cleavage sites of hemojuvelin.

Authors:  Marco Rausa; Michela Ghitti; Alessia Pagani; Antonella Nai; Alessandro Campanella; Giovanna Musco; Clara Camaschella; Laura Silvestri
Journal:  J Cell Mol Med       Date:  2015-02-22       Impact factor: 5.310

10.  Functional diversity of TMPRSS6 isoforms and variants expressed in hepatocellular carcinoma cell lines.

Authors:  Sébastien P Dion; François Béliveau; Louis-Philippe Morency; Antoine Désilets; Rafaël Najmanovich; Richard Leduc
Journal:  Sci Rep       Date:  2018-08-22       Impact factor: 4.379

View more
  9 in total

1.  Cutting not the key to TMPRSS6 activity?

Authors:  Thomas Benedict Bartnikas
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

Review 2.  The mutual crosstalk between iron and erythropoiesis.

Authors:  Clara Camaschella; Alessia Pagani; Laura Silvestri; Antonella Nai
Journal:  Int J Hematol       Date:  2022-05-27       Impact factor: 2.319

3.  Coordination of iron homeostasis by bone morphogenetic proteins: Current understanding and unanswered questions.

Authors:  Allison L Fisher; Jodie L Babitt
Journal:  Dev Dyn       Date:  2021-05-25       Impact factor: 3.780

4.  The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.

Authors:  Naja Nyffenegger; Anna Flace; Cédric Doucerain; Franz Dürrenberger; Vania Manolova
Journal:  Int J Mol Sci       Date:  2021-01-16       Impact factor: 5.923

5.  Exposure of human intestinal epithelial cells and primary human hepatocytes to trypsin-like serine protease inhibitors with potential antiviral effect.

Authors:  Erzsébet Pászti-Gere; Judit Pomothy; Ákos Jerzsele; Oliver Pilgram; Torsten Steinmetzer
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

6.  Common Single Nucleotide Polymorphism of TMPRSS6, an Iron Regulation Gene, Associated with Variable Red Blood Cell Indices in Deletional α-Globin Genotypes.

Authors:  Thidarat Suksangpleng; Waraporn Glomglao; Vip Viprakasit
Journal:  Genes (Basel)       Date:  2022-08-23       Impact factor: 4.141

7.  Functionally impaired isoforms regulate TMPRSS6 proteolytic activity.

Authors:  Sébastien P Dion; Antoine Désilets; Gabriel Lemieux; Richard Leduc
Journal:  PLoS One       Date:  2022-08-31       Impact factor: 3.752

8.  Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments.

Authors:  Michela Asperti; Elisa Brilli; Andrea Denardo; Magdalena Gryzik; Francesca Pagani; Fabiana Busti; Germano Tarantino; Paolo Arosio; Domenico Girelli; Maura Poli
Journal:  Am J Hematol       Date:  2021-08-14       Impact factor: 13.265

9.  SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.

Authors:  Ute Schaeper; George Grigoriadis; Jim Vadolas; Garrett Z Ng; Kai Kysenius; Peter J Crouch; Sibylle Dames; Mona Eisermann; Tiwaporn Nualkaew; Shahla Vilcassim
Journal:  Br J Haematol       Date:  2021-05-04       Impact factor: 6.998

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.